Ken LondonerMain MenuKen Londoner with a Device for Complex ArrhythmiaFaster and More Convenient Diagnosis in PatientsKen : Higher Prices of Medical DevicesKen Londoner Invests in Catheter AblationNew Tech Can Help Treat Atrial FibrillationKen Londoner67400b6d41c00fbf11f194dad77d72364b87b2e2Kenneth Londoner
Kenneth Londoner, as the CEO of BioSig Technologies, dedicated to developing a proprietary biomedical signal processing platform. This platform is designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals.
Raffaele Corbisiero, M.D. is responsible for conducting the evaluation of the PURE EP™ System and the collection of clinical data. Kenneth Londoner and his team are glad to commence the clinical operations at Deborah Heart and Lung Center. They are also happy to collaborate with Deborah’s physicians, because, as Londoner has recently commented, they not only utilize BioSig’s technology, but also contribute to its advancement.
In Kenneth Londoner’s opinion, taking into account the detrimental effects on cardiovascular health of COVID-19, this collaboration has begun at the best time.
Intracardiac signals are the base of everything in EP. However, Deborah’s physicians have claimed that they cannot treat something that they are not able to see. Deborah’s physicians also shared their first impressions from their early experience with PURE EP™, showing more of the cardiac signals they want to see.
Patient cases are being currently conducted by Kenneth Londoner and BioSig under the clinical trial titled “Novel Cardiac Signal Processing System for Electrophysiology Procedures (PURE EP 2.0 Study)” at Texas Cardiac Arrhythmia Research Foundation (TCARF) in Austin, Texas and Mayo Clinic Florida Campus in Jacksonville, Florida.
Kenneth Londoner has recently added to BioSig’s clinical sites the Massachusets General Hospital and the Hospital of the University of Pennsylvania.